Why the study?
Sacubitril/valsartan represents a promising approach in heart failure, prompting an evaluation of its effects compared with enalapril or valsartan in HFrEF and HFpEF.
Does sacubitril/valsartan improve clinical outcomes and symptoms compared to enalapril or valsartan in patients with heart failure?
Does sacubitril/valsartan improve clinical outcomes and symptoms compared to enalapril or valsartan in patients with heart failure?
In patients with heart failure, sacubitril/valsartan reduces first heart failure hospitalizations and improves quality of life compared to enalapril or valsartan, though it did not significantly reduce mortality in this pooled analysis.
No takes yet. Share an insight, caveat, or question.
ARNI superiority in HF supports earlier use in eligible patients; reinforces consensus and extends prior RCTs with pooled Level 1 evidence.
Jain et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: